Patents by Inventor Tanya Rhodes
Tanya Rhodes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230389553Abstract: Stable antimicrobial compositions for disinfection are disclosed. Such disinfectant compositions are highly effective in reducing, preventing and/or eradicating biofilm formation and other prevalent pathogens, have extended antimicrobial and antiviral activity for more than 24 hours, have a bio-compatible pH, are suitable for personal, clinical and surgical use and are safe to skin, mucous membranes and wounds, remain stable without precipitation, discoloration or loss of antimicrobial efficacy for at least 12 months, and are beneficial for a range of applications and uses in improving and supporting human and animal health.Type: ApplicationFiled: June 30, 2023Publication date: December 7, 2023Inventors: Douglas J. Morgan, Steve Harrison, Tanya Rhodes
-
Patent number: 11759583Abstract: Systems and methods for reducing pathogens near an implant are discussed. In some cases, the methods include reducing contaminants in a portion of a patient that has an implant and that is disposed interior to a closed surface of skin of the patient. The method can further include placing a conduit in the closed surface of skin and flowing an antimicrobial fluid into that portion of the patient to contact the antimicrobial fluid with a surface of the implant and tissue adjacent to the implant. In some cases, the antimicrobial fluid is then removed from the portion of the patient having the implant. As part of this method, biofilm near the implant can be mechanically, ultrasonically, electrically, chemically, enzymatically, or otherwise disrupted. Other implementations are described.Type: GrantFiled: August 30, 2021Date of Patent: September 19, 2023Assignee: Clyra Medical Technologies, Inc.Inventors: Spencer Brown, Brock Liden, Tanya Rhodes, Joe Almasy, Steven V. Harrison, Douglas J. Morgan
-
Patent number: 11744249Abstract: Liquid antimicrobial disinfectant compositions for treatment of coronaviruses and specifically the Covid-19 virus (SARS-CoV-2) on skin and surfaces such as PPE (personal protective equipment) are disclosed that are highly efficacious and exhibit total eradication below detectable limits at 30 minutes (>6 log kill) against coronavirus (resulting in complete inactivation), while remaining non-toxic, safe and non-irritating (including at a cellular level and with extended contact) to skin and endogenous tissue.Type: GrantFiled: August 12, 2022Date of Patent: September 5, 2023Assignee: Clyra Medical Technologies, Inc.Inventors: Douglas J. Morgan, Steve Harrison, Tanya Rhodes
-
Publication number: 20230110915Abstract: Liquid antimicrobial disinfectant compositions for treatment of coronaviruses and specifically the Covid-19 virus (SARS-CoV-2) on skin and surfaces such as PPE (personal protective equipment) are disclosed that are highly efficacious and exhibit total eradication below detectable limits at 30 minutes (>6 log kill) against coronavirus (resulting in complete inactivation), while remaining non-toxic, safe and non-irritating (including at a cellular level and with extended contact) to skin and endogenous tissue.Type: ApplicationFiled: November 7, 2022Publication date: April 13, 2023Inventors: Douglas J. MORGAN, Steve HARRISON, Tanya RHODES
-
Publication number: 20220386621Abstract: Liquid antimicrobial disinfectant compositions for treatment of coronaviruses and specifically the Covid-19 virus (SARS-CoV-2) on skin and surfaces such as PPE (personal protective equipment) are disclosed that are highly efficacious and exhibit total eradication below detectable limits at 30 minutes (>6 log kill) against coronavirus (resulting in complete inactivation), while remaining non-toxic, safe and non-irritating (including at a cellular level and with extended contact) to skin and endogenous tissue.Type: ApplicationFiled: August 12, 2022Publication date: December 8, 2022Inventors: Douglas J. MORGAN, Steve Harrison, Tanya RHODES
-
Patent number: 11457632Abstract: Liquid antimicrobial disinfectant compositions for treatment of coronaviruses and specifically the Covid-19 virus (SARS-CoV-2) on skin and surfaces such as PPE (personal protective equipment) are disclosed that are highly efficacious and exhibit total eradication below detectable limits at 30 minutes (>6 log kill) against coronavirus (resulting in complete inactivation), while remaining non-toxic, safe and non-irritating (including at a cellular level and with extended contact) to skin and endogenous tissue.Type: GrantFiled: May 14, 2020Date of Patent: October 4, 2022Assignee: CLYRA Medical Technologies, Inc.Inventors: Douglas J. Morgan, Steve Harrison, Tanya Rhodes
-
Publication number: 20210401766Abstract: A method of administering a composition having Cannabis sativa-derived substances nano-encapsulated in phospholipid vesicles for transmucosal and transdermal delivery is disclosed. A Cannabis sativa-derived formulation for transmucosal and transdermal delivery comprising Cannabis sativa-derived compounds nanoencapsulated in phospholipid-based vesicles is also disclosed. Cannabis sativa-derived extracts have enhanced bioavailability when encapsulated in nanosized phospholipid vesicles prior to administration to a subject as compared to non-encapsulated cannabinoids.Type: ApplicationFiled: September 21, 2021Publication date: December 30, 2021Applicant: NuVessl, Inc.Inventors: Tanya Rhodes, Deborah Duffey
-
Publication number: 20210386942Abstract: Systems and methods for reducing pathogens near an implant are discussed. In some cases, the methods include reducing contaminants in a portion of a patient that has an implant and that is disposed interior to a closed surface of skin of the patient. The method can further include placing a conduit in the closed surface of skin and flowing an antimicrobial fluid into that portion of the patient to contact the antimicrobial fluid with a surface of the implant and tissue adjacent to the implant. In some cases, the antimicrobial fluid is then removed from the portion of the patient having the implant. As part of this method, biofilm near the implant can be mechanically, ultrasonically, electrically, chemically, enzymatically, or otherwise disrupted. Other implementations are described.Type: ApplicationFiled: August 30, 2021Publication date: December 16, 2021Inventors: Spencer BROWN, Brock LIDEN, Tanya RHODES, Joe ALMASY, Steven V. HARRISON, Douglas J. MORGAN
-
Patent number: 11103657Abstract: Systems and methods for reducing pathogens near an implant are discussed. In some cases, the methods include reducing contaminants in a portion of a patient that has an implant and that is disposed interior to a closed surface of skin of the patient. The method can further include placing a conduit in the closed surface of skin and flowing an antimicrobial fluid into that portion of the patient to contact the antimicrobial fluid with a surface of the implant and tissue adjacent to the implant. In some cases, the antimicrobial fluid is then removed from the portion of the patient having the implant. As part of this method, biofilm near the implant can be mechanically, ultrasonically, electrically, chemically, enzymatically, or otherwise disrupted. Other implementations are described.Type: GrantFiled: December 13, 2019Date of Patent: August 31, 2021Assignee: Clyra Medical Technologies, Inc.Inventors: Spencer Brown, Brock Liden, Tanya Rhodes, Joe Almasy, Steven V. Harrison, Douglas J. Morgan
-
Patent number: 11020355Abstract: A method of encapsulating cannabis-derived compounds in nanosized phospholipid vesicles is disclosed. A Cannabis sativa-derived formulation for transmucosal and transdermal delivery comprising Cannabis sativa-derived compounds nanoencapsulated in phospholipid-based vesicles is also disclosed. Cannabis sativa-derived extracts have enhanced bioavailability when encapsulated in nanosized phospholipid vesicles prior to administration to a subject as compared to non-encapsulated cannabinoids. Also disclosed herein are methods of transmucosal and transdermal administration of the formulation having phospholipid vesicles with nanoencapsulated Cannabis sativa-derived substances.Type: GrantFiled: September 4, 2019Date of Patent: June 1, 2021Assignee: NuVessl, Inc.Inventors: Tanya Rhodes, Deborah Duffey
-
Publication number: 20200188612Abstract: Systems and methods for reducing pathogens near an implant are discussed. In some cases, the methods include reducing contaminants in a portion of a patient that has an implant and that is disposed interior to a closed surface of skin of the patient. The method can further include placing a conduit in the closed surface of skin and flowing an antimicrobial fluid into that portion of the patient to contact the antimicrobial fluid with a surface of the implant and tissue adjacent to the implant. In some cases, the antimicrobial fluid is then removed from the portion of the patient having the implant. As part of this method, biofilm near the implant can be mechanically, ultrasonically, electrically, chemically, enzymatically, or otherwise disrupted. Other implementations are described.Type: ApplicationFiled: December 13, 2019Publication date: June 18, 2020Inventors: Spencer Brown, Brock Liden, Tanya Rhodes, Joe Almasy, Steven V. Harrison, Douglas J. Morgan
-
Publication number: 20200078297Abstract: A method of encapsulating cannabis-derived compounds in nanosized phospholipid vesicles is disclosed. A Cannabis sativa-derived formulation for transmucosal and transdermal delivery comprising Cannabis sativa-derived compounds nanoencapsulated in phospholipid-based vesicles is also disclosed. Cannabis sativa-derived extracts have enhanced bioavailability when encapsulated in nanosized phospholipid vesicles prior to administration to a subject as compared to non-encapsulated cannabinoids. Also disclosed herein are methods of transmucosal and transdermal administration of the formulation having phospholipid vesicles with nanoencapsulated Cannabis sativa-derived substances.Type: ApplicationFiled: September 4, 2019Publication date: March 12, 2020Applicant: NuVessl, Inc.Inventors: Tanya Rhodes, Deborah Duffey
-
Publication number: 20200078316Abstract: A method of administering a composition having Cannabis sativa-derived substances nano-encapsulated in phospholipid vesicles for transmucosal and transdermal delivery is disclosed. A Cannabis sativa-derived formulation for transmucosal and transdermal delivery comprising Cannabis sativa-derived compounds nanoencapsulated in phospholipid-based vesicles is also disclosed. Cannabis sativa-derived extracts have enhanced bioavailability when encapsulated in nanosized phospholipid vesicles prior to administration to a subject as compared to non-encapsulated cannabinoids.Type: ApplicationFiled: September 4, 2019Publication date: March 12, 2020Applicant: NuVessl, Inc.Inventors: Tanya Rhodes, Deborah Duffey
-
Publication number: 20200078427Abstract: A Cannabis sativa-derived formulation for transmucosal and transdermal delivery is disclosed comprising Cannabis sativa-derived compounds nanoencapsulated in phospholipid-based vesicles. A method of encapsulating cannabis-derived compounds in nanosized phospholipid vesicles is also disclosed. Cannabis sativa-derived extracts have enhanced bioavailability when encapsulated in nanosized phospholipid vesicles prior to administration to a subject as compared to non-encapsulated cannabinoids. Also disclosed herein are methods of transmucosal and transdermal administration of the formulation having phospholipid vesicles with nanoencapsulated Cannabis sativa-derived substances.Type: ApplicationFiled: September 4, 2019Publication date: March 12, 2020Applicant: NuVessl, Inc.Inventors: Tanya Rhodes, Deborah Duffey
-
Publication number: 20180228837Abstract: A liquid or gel antimicrobial solution includes a) at least 80% of total weight of a carrier liquid comprising water, alcohol or a mixture of water and alcohol; b) at least 0.001% by weight of the solution of I2 further comprising KI and at least 0.001% by weight of CuSO4, and c) a metallo-peptide, the liquid or gel being substantially free of sulfamic acid. The solution or dry powder format (activated on wetting) may be carried in containers, pouches, packets, fabrics, sponges or other application systems. A dry powder composition is also available.Type: ApplicationFiled: February 15, 2017Publication date: August 16, 2018Inventors: Tanya Rhodes, Steven Harrison
-
Publication number: 20050048105Abstract: Treatments for diaper rash that include a protease inhibitor and a polymer with which the inhibitor is delivered. In certain embodiments, the inhibitor may comprises glycine soja protein or dipalmitoyl hydroxyproline. The polymer binds to the skin, creates a non-occlusive barrier, and is substantially resistant to being washed or rubbed off. The invention also relates to methods of preparing such formulations and to methods of treating patients in need of treatments for skin conditions associated with prolonged exposure to enzymes present in human waste.Type: ApplicationFiled: August 29, 2003Publication date: March 3, 2005Inventors: Amy McNulty, Tanya Rhodes
-
Patent number: 5662924Abstract: A wound dressing containing a water-insoluble, water swellable cross-linked cellulose derivative, water and a polyol component wherein the dressing comprises a gel and the cellulose derivative comprises less than 10% by weight of the gel. The dressing is easy to apply and is believed to enhance moisture penetration of necrotic tissue and thus speed up debriding action in facilitating wound healing.Type: GrantFiled: June 7, 1995Date of Patent: September 2, 1997Assignee: Smith & Nephew plcInventor: Tanya Rhodes